Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02714881 · ClinicalTrials.gov registry record
Lipids, Inflammation, and CV Risk in RA
A clinical trial of Rheumatoid Arthritis and Cardiovascular Disease, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 74
- Enrollment target
- 1
- Study location
NCT02714881 is a study of Rheumatoid Arthritis and Cardiovascular Disease that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 74 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02714881, a study of Rheumatoid Arthritis and Cardiovascular Disease, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was to examine the relationship between inflammation, lipids, and cardiovascular risk in rheumatoid arthritis. The central hypothesis is that reducing inflammation will reduce cardiovascular risk as measured by coronary flow reserve. Additionally, we hypothesized that lipid levels may have a weaker correlation with CV risk compared to the general population.
Conditions Studied
Interventions
- DRUG Certolizumab
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2016-10-17 |
| Est. Completion | 2022-12-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02714881
The ClinicalTrials.gov registry entry for NCT02714881 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Certolizumab is the first listed.
NCT02714881 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02714881 about?
NCT02714881 is a clinical study titled "Lipids, Inflammation, and CV Risk in RA". The objective of this study was to examine the relationship between inflammation, lipids, and cardiovascular risk in rheumatoid arthritis. The central hypothesis is that reducing inflammation will reduce cardiovascular risk as measured by coronary flow reserve. Additionally, we hypothesized that lip...
What is the current status of trial NCT02714881?
This trial is currently completed. The enrollment target is 74 participants. The study started on 2016-10-17. Estimated completion is 2022-12-21.
What conditions does trial NCT02714881 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis, Cardiovascular Disease.
What interventions are being tested in trial NCT02714881?
The interventions under investigation include: Certolizumab (DRUG).
Who is sponsoring clinical trial NCT02714881?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02714881 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
RECRUITING · NA
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Physica System Total Knee Replacement Registry Study
RECRUITING · NA
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.